110 related articles for article (PubMed ID: 24811330)
1. KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?
Scott RJ; Fox SB; Desai J; Grieu F; Amanuel B; Garrett K; Harraway J; Cheetham G; Pattle N; Haddad A; Byron K; Rudzki B; Waring P; Iacopetta B
Asia Pac J Clin Oncol; 2014 Sep; 10(3):261-5. PubMed ID: 24811330
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
3. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
4. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
5. [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].
Mazurenko NN; Gagarin IM; Tsyganova IV; Mochal'nikova VV; Breder VV
Vopr Onkol; 2013; 59(6):751-5. PubMed ID: 24624786
[TBL] [Abstract][Full Text] [Related]
6. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.
Ross JS
Arch Pathol Lab Med; 2012 Oct; 136(10):1298-307. PubMed ID: 22272560
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
8. [KRAS gene somatic mutations in Chilean patients with colorectal cancer].
Hurtado C; Encina G; Wielandt AM; Zárate AJ; Castro M; Carrillo K; Kronberg U; López-Köstner F
Rev Med Chil; 2014 Nov; 142(11):1407-14. PubMed ID: 25694286
[TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
11. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
[No Abstract] [Full Text] [Related]
12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
Kawamoto Y; Yoshino T
Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
[No Abstract] [Full Text] [Related]
14. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
15. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of KRAS mutations in patients with colorectal cancer.
Inoue Y; Saigusa S; Iwata T; Okugawa Y; Toiyama Y; Tanaka K; Uchida K; Mohri Y; Kusunoki M
Oncol Rep; 2012 Nov; 28(5):1579-84. PubMed ID: 22922794
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Shibuya H; Eshima K
Dis Colon Rectum; 2011 Sep; 54(9):1170-8. PubMed ID: 21825899
[TBL] [Abstract][Full Text] [Related]
18. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
19. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Santini D; Loupakis F; Vincenzi B; Floriani I; Stasi I; Canestrari E; Rulli E; Maltese PE; Andreoni F; Masi G; Graziano F; Baldi GG; Salvatore L; Russo A; Perrone G; Tommasino MR; Magnani M; Falcone A; Tonini G; Ruzzo A
Oncologist; 2008 Dec; 13(12):1270-5. PubMed ID: 19056857
[TBL] [Abstract][Full Text] [Related]
20. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.
Han CB; Li F; Ma JT; Zou HW
Cancer Invest; 2012 Dec; 30(10):741-7. PubMed ID: 23075074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]